Q2 Earnings Forecast for TG Therapeutics Issued By B. Riley

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities research analysts at B. Riley issued their Q2 2025 earnings per share estimates for TG Therapeutics in a research note issued on Tuesday, March 4th. B. Riley analyst M. Mamtani anticipates that the biopharmaceutical company will post earnings per share of $0.27 for the quarter. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. B. Riley also issued estimates for TG Therapeutics’ Q3 2025 earnings at $0.26 EPS, Q4 2025 earnings at $0.28 EPS, FY2025 earnings at $1.03 EPS, FY2027 earnings at $2.78 EPS, FY2028 earnings at $3.85 EPS and FY2029 earnings at $4.74 EPS.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. The business had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%.

Several other brokerages also recently weighed in on TGTX. JPMorgan Chase & Co. increased their target price on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. HC Wainwright reissued a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. Finally, StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Trading Up 9.2 %

Shares of NASDAQ:TGTX opened at $38.44 on Friday. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The stock’s 50-day moving average is $31.07 and its 200-day moving average is $28.55. The company has a market cap of $5.98 billion, a P/E ratio of -384.36 and a beta of 2.30. TG Therapeutics has a 52-week low of $12.93 and a 52-week high of $38.58.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vermillion Wealth Management Inc. acquired a new position in shares of TG Therapeutics in the 4th quarter worth approximately $30,000. Quadrant Capital Group LLC raised its stake in TG Therapeutics by 137.1% during the fourth quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company’s stock worth $51,000 after acquiring an additional 975 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 371 shares during the period. Smartleaf Asset Management LLC boosted its stake in shares of TG Therapeutics by 512.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 1,594 shares in the last quarter. Finally, Jones Financial Companies Lllp boosted its stake in shares of TG Therapeutics by 460.7% in the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock valued at $64,000 after purchasing an additional 1,737 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.

Insider Activity at TG Therapeutics

In related news, CFO Sean A. Power sold 10,021 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the sale, the chief financial officer now owns 660,611 shares of the company’s stock, valued at $18,847,231.83. The trade was a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 10.50% of the stock is currently owned by corporate insiders.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.